Ac-225-MTI-201
225Ac-MTI-201, formerly 225Ac-DOTA-MC1RL, is a melanocortin 1 receptor ligand labeled [...]
Ac-225-FPI-2068
225Ac-FPI-2068 is a targeted alpha therapy (TAT) designed to deliver [...]
Ac-225-DOTA-YS5
225Ac-DOTA-YS5 is a CD46-targeted PET radiopharmaceutical under evaluation for therapeutic [...]
Ac-225-FPI-2265
225Ac-FPI-2265 (225Ac-PSMA-I&T) is another alpha emitter analogue of the marketed [...]
Ac-225-FPI-2059
225Ac-FPI-2059 (225Ac-3BP-227, 225Ac-IPN-01087) is the 225Ac-labeled analogue of 177Lu-IPN-1087, a [...]
Ac-225-DOTA-SP
225Ac-DOTA-SP (225Ac-Substance-P) is developed as local treatment for glioblastoma and [...]
Ac-225-PSMA-617
225Ac-PSMA-617 is the next generation of prostate cancer treatment following [...]
Ac-225-Lintuzumab (Ac-225 Actimab-A™)
225Ac-Lintuzumab (225Ac-Actimab-A™, 225Ac-DOTA-huM195) is the new name of the lead [...]
Ac-225-FPI-1434
225Ac-FPI-1434 (225Ac-FPX-01) is an alpha labeled antibody under development for [...]
Ac-225-DOTAZOL
225Ac-DOTAZOL is a DOTA Zoledronic acid derivative suitable for alphatherapy [...]